State Street Corp Purchases 27,628 Shares of Cardiff Oncology, Inc. (NASDAQ:CRDF)

State Street Corp raised its position in shares of Cardiff Oncology, Inc. (NASDAQ:CRDF) by 3.4% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 832,652 shares of the company’s stock after buying an additional 27,628 shares during the quarter. State Street Corp owned about 1.63% of Cardiff Oncology worth $2,223,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of CRDF. Bank of New York Mellon Corp purchased a new stake in Cardiff Oncology during the second quarter valued at approximately $256,000. Rhumbline Advisers purchased a new stake in shares of Cardiff Oncology during the 2nd quarter valued at $102,000. Ground Swell Capital LLC acquired a new stake in shares of Cardiff Oncology in the 2nd quarter worth $38,000. American Century Companies Inc. boosted its position in shares of Cardiff Oncology by 98.7% in the 2nd quarter. American Century Companies Inc. now owns 45,360 shares of the company’s stock worth $101,000 after purchasing an additional 22,536 shares in the last quarter. Finally, Thoroughbred Financial Services LLC purchased a new position in Cardiff Oncology during the 2nd quarter worth $116,000. 16.29% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts have weighed in on the company. HC Wainwright lowered their price target on Cardiff Oncology from $14.00 to $13.00 and set a “buy” rating for the company in a report on Friday, November 8th. Piper Sandler boosted their target price on shares of Cardiff Oncology from $7.00 to $10.00 and gave the stock an “overweight” rating in a research report on Friday, December 13th. Finally, Craig Hallum started coverage on shares of Cardiff Oncology in a report on Friday, September 6th. They issued a “buy” rating and a $8.00 price target for the company.

Cardiff Oncology Stock Performance

Shares of CRDF stock opened at $4.34 on Thursday. Cardiff Oncology, Inc. has a fifty-two week low of $1.44 and a fifty-two week high of $6.42. The firm has a market capitalization of $221.92 million, a PE ratio of -4.62 and a beta of 1.89. The stock’s 50-day simple moving average is $3.31 and its 200-day simple moving average is $2.73.

Insider Activity at Cardiff Oncology

In other Cardiff Oncology news, Director Gary W. Pace bought 350,115 shares of Cardiff Oncology stock in a transaction that occurred on Wednesday, December 11th. The stock was purchased at an average price of $2.60 per share, with a total value of $910,299.00. Following the completion of the acquisition, the director now directly owns 1,047,876 shares in the company, valued at approximately $2,724,477.60. This trade represents a 50.18 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 7.80% of the stock is owned by insiders.

Cardiff Oncology Company Profile

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.